REG - Genedrive PLC - NICE to evaluate the Genedrive® MT-RNR1 Test

GenedriveAnnouncement

16/06/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220616:nRSP0121Pa&default-theme=true

RNS Number : 0121P  Genedrive PLC  16 June 2022

genedrive plc

("genedrive" or the "Company")

 

NICE to evaluate the Genedrive® MT-RNR1 Test under their Diagnostics
Assessment Programme

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company,
announces that the UK's National Institute for Health and Clinical Excellence
('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their
Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to
provide robust recommendations on the use of new products, which is presented
in the form of NICE guidance, and to promote rapid and consistent adoption of
clinically innovative and cost-effective diagnostic technologies in the NHS.

 

An independent advisory committee considers the evidence provided, makes draft
recommendations for public consultation and ultimately makes final
recommendations for publication in NICE guidance. The guidance produced is
used by NHS commissioners, practitioners, healthcare operational managers and
purchasing and procurement organisations.

 

genedrive's assay is the world's first rapid point of care test to screen
infants in an urgent care setting for a genetic variant that will cause
life-long hearing loss when carriers of the variant are given certain
antibiotics. Those that carry the variant can then be given alternative
treatments following detection of the variant by the Genedrive® MT-RNR1 test.

 

David Budd, CEO of genedrive plc, said: "We are grateful to NICE for their
engagement and interest in our innovative technology and pleased that the
Genedrive® MT-RNR1 test was selected for this programme following successful
publication of the NICE Medtech innovation briefing ("MIB290") in March. The
NICE guidance is an important element required to drive uptake and adoption of
the test in the NHS by demonstrating the cost-saving efficiencies. The
application of Genedrive's technology shows how a rapid, affordable,
point-of-care test could impact patients' treatment and quality of life."

 

For further details please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash / Kate Bannatyne / Alice Lane

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The Company has assays on market for
the detection of MT-RNR1, HCV, certain military biological targets, and a high
throughput SARS-CoV-2 assay.  The Company recently released a point of care
test for Covid-19.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUBUQUPPGWA